MB
Therapeutic Areas
Saverna Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| pre-miRNA targeting program | Undisclosed (within inflammation, autoimmune, cancer, or infection) | Pre-clinical |
Leadership Team at Saverna Therapeutics
KA
Kamal Azzaoui, PhD
CEO, Co-Founder
MG
Marjo Götte, PhD
Director Biology, Co-founder
HF
Heinz Fretz, PhD
Director Chemistry